PT - JOURNAL ARTICLE AU - Stoddard, Madison AU - Yuan, Lin AU - Chakravarty, Arijit TI - Using translational <em>in vitro-in vivo</em> modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics AID - 10.1101/2021.03.11.21253375 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.11.21253375 4099 - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253375.short 4100 - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253375.full AB - The ongoing COVID-19 pandemic has created an urgent need for antiviral treatments that can be deployed rapidly. Drug repurposing represents a promising means of achieving this objective, but repurposing efforts are often unsuccessful. A common hurdle to effective drug repurposing is a failure to achieve a sufficient therapeutic window in the new indication. A clear example is the use of ivermectin in COVID-19, where the approved dose (administered orally) fails to achieve therapeutic concentrations in the lungs. Our proposed solution to the problem of ineffective drug repurposing for COVID-19 antivirals is two-fold: to broaden the therapeutic window by reformulating therapeutics for the pulmonary route, and to select drug repurposing candidates based on their model-predicted therapeutic index for inhalation. In this article, we propose a two-stage model-driven screening and validation process for selecting inhaled antiviral drug repurposing candidates. While we have applied this approach in the specific context of COVID-19, this in vitro-in vivo translational methodology is also broadly applicable to repurposing drugs for diseases of the lower respiratory tract.Competing Interest StatementMS, LY and AC are shareholders and employees of Fractal Therapeutics Inc. This work was funded by Fractal Therapeutics. Fractal Therapeutics does not benefit in any way from sharing the work here (strategy for identifying new antiviral combinations) with potential competitors. Funding StatementLY and MS's salaries were paid by Fractal Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe work describes a mathematical methodology based on publicly available data. All data used in the work was sourced from prior publications.